循环分子组件用于选择性癌细胞高尔基干扰
bioRxiv : the preprint server for biology
|January 13, 2025
概括
研究人员开发了新的循环分子组件 (CyMA),可以选择性地向癌细胞中的戈尔吉装置. 这一突破破坏了癌细胞的功能,为各种病理提供了新的治疗策略.
科学领域:
- 细胞生物学 细胞生物学
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 戈尔吉装置对于细胞内交易和信号传输至关重要,其功能障碍与癌症等疾病有关.
- 向戈尔吉装置提供了治疗机会,但选择性细胞向仍然是一个挑战.
- 现有的方法缺乏细胞选择性,需要针对高尔基特异性癌症干扰的创新策略.
研究的目的:
- 开发新的小衍生物,循环分子组件 (CyMA),用于选择性戈尔吉装置向癌细胞.
- 为了利用戈尔吉独特的酶环境进行有针对性的治疗干预.
- 研究CyMA在破坏癌细胞功能和进展方面的潜力.
主要方法:
- 基于小衍生物的循环分子组件 (CyMA) 的开发.
- 利用高尔基特异性酶活动 (例如蛋白酸转移酶) 来建立无用的S-化循环.
- 评估CyMA在Golgi癌细胞中的选择性积累以及对有机细胞平衡的影响.
主要成果:
- 赛马选择性地积聚在Golgi癌细胞中,破坏蛋白质S-化和有机细胞平衡.
- 赛马会损害关键的戈尔吉功能,包括蛋白质的贩运,糖化和分泌.
- 赛马证明了选择性节省肝细胞和M1巨细胞,减少瘤生长,药物耐药性和转移.
结论:
- 循环分子组合 (CyMA) 是一种新的治疗策略,利用器官特异性酶活动.
- 这种方法提供了一种可通用的方法来准特定的器官功能,特别是在癌症中.
- CyMA对癌症和其他与戈尔吉相关的疾病具有显著的治疗潜力.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Assembly of Cytoskeletal Filaments
17.2K
Cytoskeletal filaments are polymeric forms of smaller protein subunits. However, individual cytoskeletal filaments may easily disassemble or associate with other similar filaments to form rigid structures. Microfilaments, made of actin monomers, rely on actin-binding proteins to form bundles and create networks of individual actin filaments. Microtubules rely on microtubule-associated proteins (MAPs) to form sturdy cylindrical structures. However, the proteins involved in forming complex...
17.2K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


